<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1703257080
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SALAZOPYRIN-EN TAB 500MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SULFASALAZINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        28.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Recipharm Uppsala AB" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Recipharm Uppsala AB
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer AB
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A07EC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Salazopyrin EN has an anti-inflammatory and an antibacterial effect and reduces inflammation, particularly in the intestinal mucosa.</p><p>Salazopyrin EN is a gastro-resistant tablet specially intended for patients with active rheumatoid arthritis and for patients that experience gastrointestinal side effects from Salazopyrin tablets.</p><p>&nbsp;</p><p>Salazopyrin EN is used to treat arthritis of the joints and inflammatory bowel diseases (ulcerative colitis, Crohns disease).</p><p>Salazopyrin is also used to treat the skin disease pyoderma gangraenosum, which is sometimes seen in patients with ulcerative colitis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Salazopyrin EN</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to sulfasalazine, its metabolites, sulpha (sulfonamides) or salicylates (contained in some medicines against fever and pain) or any of the other ingredients of this medicine (see section 6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have acute intermittent porphyria (liver porphyria, increase in certain haemoglobins caused by an enzyme deficiency).</p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>Talk with your doctor or pharmacist before taking Salazopyrin EN.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have recurrent or chronic infections</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have decreased kidney or liver function</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe allergy or asthma</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have glucose-6-phosphate-dehydrogenase deficiency, you should inform your doctor before the start of treatment.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are male and trying to have children because Salazopyrin EN can decrease sperm production (returns to normal once the medication has been stopped)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken Salazopyrin EN, or any other sulfasalazine containing products, because they may affect results of blood and urine tests.</p><p>&nbsp;</p><p>Contact your doctor immediately if you develop a new infection during treatment with Salazopyrin EN. Your doctor may stop the treatment.</p><p>&nbsp;</p><p>Your blood cell count, kidney and liver function should be monitored before treatment begins and at the beginning of treatment. Contact should be maintained with the treating doctor for regular examinations.</p><p>&nbsp;</p><p>Contact your doctor immediately if you experience symptoms such as sore throat or fever, or if your skin is pale or has a reddish or yellowish color. This may be a sign of liver problems and blood cell changes and treatment may need to be discontinued.</p><p>&nbsp;</p><p>Skin reactions, which may be life threatening (Stevens-Johnson syndrome and toxic epidermal necrolysis), have been reported with sulfasalazine. This may begin as purplish target-like or round spots with blisters in the middle, often symmetrically distributed, on the torso. Additional signs to look out for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). Skin reactions which can be life-threatening are often accompanied by flu-like symptoms. The rash may develop into blisters over large areas, or peeling of the skin. The risk of serious skin reactions is greatest during the first weeks of treatment. If you have experienced Stevens-Johnson syndrome or toxic epidermal necrolysis while using sulfasalazine, which is contained in Salazopyrin EN, you must never use medicines containing sulfasalazine again. If you get a rash or signs of these skin reactions, you must immediately stop taking Salazopyrin EN, and immediately contact a doctor and inform the doctor that you are taking this medicine.</p><p>&nbsp;</p><p>Hypersensitivity reactions that may be life threatening (such as medicine-induced rash (DRESS)), have been reported with sulfasalazine. Early signs of hypersensitivity may include rash, fever or swollen lymph nodes. If you experience symptoms of a hypersensitivity reaction, you should immediately contact your doctor and tell your doctor that you are taking this medicine.</p><p>&nbsp;</p><p>During treatment with sulfasalazine it is important to drink plenty of water to prevent the formation of crystals in the urine or kidney stones.</p><p>&nbsp;</p><p><strong>Other medicines and Salazopyrin EN</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription. The treatment effect can be affected if Salazopyrin EN are used concomitant with other drugs. If you are being treated with any of the medicines mentioned below, the dose of Salasopyrin EN or the other medicine may need to be adjusted or other precautions may be required.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin for cardiac disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Folic acid for anaemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin for tuberculosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Mercaptopurine or azathioprine for leukopaenia or transplantation and immunological diseases.</p><p>&nbsp;</p><p><strong>Salazopyrin EN with food and drink</strong></p><p>The enteric coated tablets should preferably be taken with a meal and should be evenly distributed throughout the day. The tablets are coated so that they do not dissolve until they reach the intestine. It is important that the tablets are <em>swallowed whole</em> so that the outer layer (coating) is not damaged.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feedning</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Treatment with Salazopyrin EN can lead to folic acid deficiency.</p><p>&nbsp;</p><p>The concentration of medicine can be expected to be the same in the mother and the foetus and therefore there is a risk of side effects for the foetus as well. Animal studies do not indicate any risks for the foetus; however, risks associated with use during pregnancy cannot be entirely excluded. Salazopyrin EN should only be given during pregnancy after special consideration by a doctor.</p><p>&nbsp;</p><p>Salazopyrin EN passes into breast milk in small amounts. Bloody stools and diarrhoea have been reporting in infants when the breast-feeding mother has been treated with sulfasalazin.</p><p>&nbsp;</p><p><strong>Driving</strong><strong> and using machines</strong></p><p>No effects have been observed.</p><p>&nbsp;</p><p><strong>Salazopyrin EN contains propylene glycol</strong></p><p>This medicine contains 5 mg propylene glycol in each tablet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Salazopyrin EN exactly as your doctor has told you. Check with your doctor if you are not sure. The dose is individually adjusted for you. Follow carefully the dose instructions on the label from the pharmacy.</p><p>&nbsp;</p><p><em>In rheumatoid arthritis:</em></p><p>Usual dose, adults: 2 tablets 2 times a day.</p><p><em>&nbsp;</em></p><p><em>In inflammatory bowel disease:</em></p><p>Usual dose, adults: 2-4 tablets 2-4 times a day.</p><p>Usual dose, children: the dose is dependent on the weight of the child.</p><p>&nbsp;</p><p><strong>If you take more Salazopyrin EN than you should </strong></p><p>If you have taken more Salazopyrin EN than you should, or if children have been taking medicine by accident, please contact your doctor, the hospital to get an opinion of the risk and advice on action to be taken.</p><p>&nbsp;</p><p><strong>If you forget to take Salazopyrin EN </strong></p><p>Do not take a double dose to make up for a forgotten dose. Medication should continue for as long as the doctor has prescribed it, as otherwise the disease could worsen or reappear. Usually Salazopyrin EN is used during a long period of time.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Hypersensitivity reactions can occur in rare occations.</p><p>&nbsp;</p><p>Any side effects will most often appear during the first 3 months of Salazopyrin EN treatment.</p><p>&nbsp;</p><p>Common side effects<em> </em>(affects more than 1 in 100 users)</p><ul><li>Reduced leukocytes (white blood cells)</li><li>loss of appetite</li><li>headache, dizziness, taste changes</li><li>ringing in the ears</li><li>cough</li><li>nausea, stomach pain, bloating, diarrhoea, vomiting</li><li>hives</li><li>itch</li><li>purple discolouration of the skin</li><li>joint pain</li><li>protein in the urine</li><li>decreased sperm production (reversible)</li><li>fever</li><li>temporary elevation of liver enzymes<em> </em></li></ul><p>Uncommon side effects<em> </em>(may affect less than 1 in 100 users)</p><ul><li>reduced amount thrombocytes (blood platelets)</li><li>facial swelling</li><li>depression,</li><li>difficulty breathing</li><li>hair loss</li></ul><p>Rare side effects (affects fewer than 1 in 1,000 users)</p><ul><li>nail changes, skin reactions which may be life-threatening (epidermal necrolysis and Stephens-Johnson syndrome)</li><li>jaundice</li></ul><p>Have been reported<em> </em>(affecting an unknown amount of users)</p><ul><li>pseudomembranous colitis (intestinal inflammation)</li><li>mononucleosis syndrome (false mononucleosis)</li><li>blood count changes, including severe lack of white blood cells (agranulocytosis) and severe anaemia</li><li>hypersensitivity reactions, angiooedema (swelling of lips, eyelids, face, tongue and throat), serum sickness (delayed allergic reaction)</li><li>folic acid deficiency</li><li>nervous system disorder, encephalitis, encephalopathy (brain disease), altered sense of smell, heart muscle inflammation</li><li>pericarditis, oxygenation of the blood which leads to bluish discoloration of skin, lips, and mucous membranes (cyanosis) and pallor</li><li>various lung diseases (such as fibrosing alveolitis), pain in the mouth and throat</li><li>pancreatitis, exacerbation of ulcerative colitis</li><li>liver dysfunction, sometimes occurring suddenly, liver failure, narrowing of the bile ducts in the liver and slower flow of bile in the gallbladder</li><li>medicine-induced rash (DRESS - see also Warnings and Precautions), skin rash, skin redness, severe skin inflammation with scaling (exfoliative dermatitis), skin reactions to sun exposure</li><li>SLE syndrome (autoimmune disease)</li><li>kidney dysfunction, blood in the urine, crystals in the urine, kidney stones</li><li>yellow discoloration of skin and body fluids (e.g., sweat, saliva, urine, and tear fluid) and thus the yellowing of soft contact lenses</li><li>formation of antibodies directed against the body&rsquo;s tissues (called auto-antibodies)</li></ul><p>&nbsp;</p><p>If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.</p><p>&nbsp;</p><p>You should stop taking Salazopyrin EN and see your doctor immediately if you experience symptoms of angioedema, such as</p><p>&bull; swollen face, tongue or pharynx</p><p>&bull; difficulty to swallow</p><p>&bull; hives and difficulties to breath</p><p>&nbsp;</p><p>Skin reactions, which may be life-threatening (Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported (see Warnings and Precautions).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><ul><li>SFDA Call center: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li></ul><p>&middot;&nbsp;&nbsp; &nbsp;&nbsp;Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Shelf life: 48 months.</p><p>&nbsp;</p><p>Store below 25℃.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of that month. Shelf life: 48 months.</p><p>&nbsp;</p><p>Store below 25℃.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Container (HD-polyethylene) with screw lid (polyprophylene), 100 units. The lid has a groove for easy opening with a tool such as a pen.

The tablet is yellow, round, with engraved symbol.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorisation Holder:</u></p><p>Pfizer AB, Sweden</p><p>&nbsp;</p><p>&nbsp;<u>Manufacturer</u><strong>:</strong></p><p>Recipharm Uppsala AB, Sweden</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2023.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سالازوبيرين إي إن له تأثير مضاد للالتهاب ومضاد للبكتيريا، وهو يقلل الالتهاب خاصةً في الغشاء المخاطي المعوي.</p><p dir="RTL">سالازوبيرين إي إن هو قرص مقاوم لأحماض المعدة مُخصص تحديدًا للمرضى المصابين بالتهاب المفاصل الروماتويدي النشط وللمرضى الذين يعانون من آثار جانبية معدية معوية ناتجة عن تناول أقراص سالازوبيرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم سالازوبيرين إي إن لعلاج التهاب المفاصل وأمراض الأمعاء الالتهابية (التهاب القولون التقرحي، مرض كرون).</p><p dir="RTL">يستخدم سالازوبيرين أيضًا لعلاج المرض الجلدي المُسمى تقيح الجلد الغنغريني، الذي يُلاحظ ظهوره أحيانًا لدى المرضى المصابين بالتهاب القولون التقرحي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال سالازوبيرين إي إن</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية تجاه سلفاسالازين، أو نواتج أيضه، أو السلفا (مركبات السلفوناميد)، أو مركبات الساليسيلات (الموجودة في بعض الأدوية المضادة للحمى والألم)، أو تجاه أي من المكونات الأخرى لهذا الدواء (انظر القسم ٦).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالبرفيرية الحادة المتقطعة (البرفيرية الكبدية، زيادة في هيموجلوبينات معينة بسبب نقص أحد الإنزيمات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال سالازوبيرين إي إن </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل تناول سالازوبيرين إي إن</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بحالات عدوى متكررة أو مزمنة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض في وظائف الكلى أو الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية الشديدة أو الربو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نقص إنزيم نازعة هيدروجين الجلوكوز-٦-فوسفات، ينبغي أن تبلغ طبيبك قبل بدء العلاج</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت ذكرًا وتسعى لإنجاب الأطفال، نظرًا لأن سالازوبيرين إي إن يمكن أن يقلل من إنتاج الحيوانات المنوية (يعود إلى المعدل الطبيعي بمجرد إيقاف الدواء)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخرًا سالازوبيرين إي إن، أو أي منتجات أخرى تحتوي على سلفاسالازين، لأنها قد تؤثر على نتائج اختبارات الدم والبول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا أصبت بعدوى جديدة أثناء العلاج بسالازوبيرين إي إن. فقد يقوم طبيبك بإيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تنبغي مراقبة تعداد خلايا الدم ووظائف الكلى والكبد لديك قبل بدء العلاج وفي بداية فترة العلاج. وينبغي استمرار التواصل مع الطبيب المعالج لإجراء فحوصات منتظمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك على الفور إذا أصبت بأعراض مثل التهاب الحلق أو الحمى، أو إذا كان لون جلدك شاحبًا أو مائلًا للحمرة أو الصفرة. فقد يكون ذلك علامة على وجود مشكلات بالكبد وتغيرات في خلايا الدم، وقد يلزم إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث تفاعلات جلدية قد تكون مهددة للحياة (متلازمة ستيفنز جونسون وتقشر الأنسجة المتموتة البشروية التسممي) مع استخدام سلفاسالازين. قد تبدأ هذه التفاعلات في صورة بقع مائلة إلى اللون الأرجواني تأخذ شكل لوحة التصويب أو دوائر بها بثور في المنتصف، وغالبًا ما تكون متوزعة بشكل متماثل على الجذع. تتضمن العلامات الإضافية التي ينبغي الانتباه لها الإصابة بقرح في الفم، والحلق، والأنف، والأعضاء التناسلية، والتهاب الملتحمة (احمرار وتورم العينين). التفاعلات الجلدية التي يمكن أن تكون مهددة للحياة غالبًا ما تصاحبها أعراض شبيهة بالإنفلوانزا. قد يتطور الطفح الجلدي إلى بثور تنتشر على مناطق كبيرة من الجلد، أو تقشر للجلد. يكون خطر الإصابة بالتفاعلات الجلدية الخطيرة في أقصى درجاته خلال الأسابيع الأولى من العلاج. إذا كنت قد أصبت بمتلازمة ستيفنز جونسون أو تقشر الأنسجة المتموتة البشروية التسممي أثناء استخدام سلفاسالازين، الموجود في سالازوبيرين إي إن، يجب ألا تستخدم أدوية تحتوي على سلفاسالازين مرة أخرى أبدًا. إذا أصبت بطفح جلدي أو إذا ظهرت عليك علامات لهذه التفاعلات الجلدية، يجب أن تتوقف عن تناول سالازوبيرين إي إن فورًا، ويجب أن تتصل بطبيب على الفور وتخبره أنك تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث تفاعلات فرط حساسية قد تكون مهددة للحياة (مثل الطفح الجلدي الناتج عن الدواء (التفاعل الدوائي المصحوب بكثرة اليوزينيات وأعراض جهازية (DRESS))( مع استخدام سلفاسالازين. قد تتضمن العلامات المبكرة لفرط الحساسية الطفح الجلدي، أو الحمى، أو تورم العقد الليمفاوية. إذا أصبت بأعراض لأحد تفاعلات فرط الحساسية، ينبغي أن تتصل بطبيبك على الفور وتخبره أنك تتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء العلاج بسلفاسالازين، من المهم أن تشرب كمية وفيرة من الماء لمنع تكوّن بلورات في البول أو حصوات في الكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى، بما في ذلك الأدوية التي يتم الحصول عليها دون وصفة طبية. يمكن أن تتأثر فعالية العلاج إذا تم استخدم سالازوبيرين إي إن بالتزامن مع عقاقير أخرى. إذا كنت تخضع للعلاج بأي من الأدوية المذكورة أدناه، فقد يلزم تعديل جرعة سالازوبيرين إي إن أو جرعة الدواء الآخر، أو قد يلزم اتخاذ احتياطات أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين لعلاج مرض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حمض الفوليك لعلاج فقر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين لعلاج السل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ميركابتوبيورين أو آزاثيوبرين لعلاج قلة الكريات البيضاء أو لعلاج الأمراض المناعية وفي عمليات زراعة الأعضاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول سالازوبيرين إي إن مع الطعام والشراب</strong></p><p dir="RTL">يُفضل أن يتم تناول الأقراص المغلفة بغشاء معوي مع الوجبات، وينبغي توزيعها بشكل متساوِ على مدار اليوم. الأقراص مغلفة حتى لا تذوب إلا بعد أن تصل إلى الأمعاء. من المهم أن يتم <em>بلع الأقراص كاملةً</em> حتى لا تتلف الطبقة الخارجية (الغلاف).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي العلاج بسالازوبيرين إي إن إلى نقص حمض الفوليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن توقع أن يكون تركيز الدواء متماثلًا لدى الأم والجنين، وبالتالي فالجنين معرض أيضًا لخطر الإصابة بالآثار الجانبية. لا تشير الدراسات المُجراة على الحيوانات إلى تعرض الجنين لأي مخاطر؛ وعلى الرغم من ذلك فالمخاطر المرتبطة بالاستخدام أثناء الحمل لا يمكن استبعادها تمامًا. ينبغي إعطاء سالازوبيرين إي إن أثناء الحمل فقط بعد أن يقوم طبيب بدراسة هذا الأمر بشكل خاص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمر سالازوبيرين إي إن إلى لبن الثدي بكميات صغيرة. تم الإبلاغ عن حدوث حالات براز دموي وإسهال لدى الرضع عندما كانت الأمهات المرضعات تخضعن للعلاج بسلفاسالازين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير سالازوبيرين إي إن على القيادة واستخدام الآلات</strong></p><p dir="RTL">لم تتم ملاحظة أي تأثيرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات سالازوبيرين إي إن</strong></p><p dir="RTL"><strong>يحتوي سالازوبيرين إي إن على بروبيلين جليكول</strong></p><p dir="RTL">يحتوي هذا الدواء على ٥ ملجم من بروبيلين جليكول في كل قرص.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">احرص دائمًا على تناول سالازوبيرين إي إن تمامًا كما أخبرك طبيبك. راجع طبيبك إذا لم تكن متأكدًا مما يجب عليك فعله. يتم تعديل الجرعة بشكل فردي لتناسب حالتك. اتبع بدقة التعليمات الخاصة بالجرعة المدونة على الملصق من الصيدلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>في حالة التهاب المفاصل الروماتويدي:</em></p><p dir="RTL">الجرعة المعتادة، للبالغين: قرصان مرتين في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>في حالة مرض الأمعاء الالتهابي:</em></p><p dir="RTL">الجرعة المعتادة، للبالغين: من قرصين إلى ٤ أقراص مرتين إلى ٤ مرات في اليوم.</p><p dir="RTL">الجرعة المعتادة، للأطفال: تعتمد الجرعة على وزن الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من سالازوبيرين إي إن </strong></p><p dir="RTL">إذا تناولت كمية أكبر مما ينبغي من سالازوبيرين إي إن أو إذا تناول طفل الدواء عن طريق الخطأ، يرجى الاتصال بطبيبك أو بالمستشفى &nbsp;لتلقي فكرة حول المخاطر وتلقي المشورة حول الإجراءات التي ينبغي اتخاذها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة سالازوبيرين إي إن </strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة منسية. ينبغي الاستمرار في تناول الدواء طوال الفترة التي حددها الطبيب، وإلا فقد يتفاقم المرض أو يعاود الظهور مرة أخرى.</p><p dir="RTL">المعتاد أن يستخدم سالازوبيرين إي إن خلال فترة طويلة من الوقت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع. يمكن أن تحدث تفاعلات فرط الحساسية في حالات نادرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف تظهر أي آثار جانبية في الأغلب خلال أول ٣ أشهر من العلاج بسالازوبيرين إي إن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الشائعة<em> </em>(تصيب أكثر من مستخدم واحد من بين كل ١٠٠ مستخدم)</p><ul><li dir="RTL">انخفاض عدد الكريات البيضاء (خلايا الدم البيضاء)</li><li dir="RTL">فقدان الشهية</li><li dir="RTL">الصداع، الدوار، تغيرات في حاسة التذوق</li><li dir="RTL">طنين في الأذنين.</li><li dir="RTL">السعال</li><li dir="RTL">الغثيان، ألم المعدة، الانتفاخ، الإسهال، القيء</li><li dir="RTL">الشرى</li><li dir="RTL">الحكة</li><li dir="RTL">تغير لون الجلد إلى اللون الأرجواني</li><li dir="RTL">ألم المفاصل</li><li dir="RTL">وجود بروتين في البول</li><li dir="RTL">انخفاض إنتاج الحيوانات المنوية (قابل للعكس)</li><li dir="RTL">الحمى</li><li dir="RTL">ارتفاع مؤقت في مستويات إنزيمات الكبد.<em> </em></li></ul><p dir="RTL">الآثار الجانبية غير الشائعة<em> </em>(قد تصيب أقل من مستخدم واحد من بين كل ١٠٠ مستخدم)</p><ul><li dir="RTL">انخفاض عدد الصفيحات (الصفائح الدموية)</li><li dir="RTL">تورم الوجه</li><li dir="RTL">الاكتئاب</li><li dir="RTL">صعوبة التنفس</li><li dir="RTL">تساقط الشعر</li></ul><p dir="RTL">الآثار الجانبية النادرة (تصيب ما يقل عن مستخدم واحد من بين كل ١٠٠٠ مستخدم)</p><ul><li dir="RTL">تغيرات في الأظافر، تفاعلات جلدية قد تكون مهددة للحياة (تقشر الأنسجة المتموتة البشروية ومتلازمة ستيفنز جونسون)</li><li dir="RTL">اليرقان</li></ul><p dir="RTL">تم الإبلاغ عنها (تصيب عدد غير معروف من المستخدمين)</p><ul><li dir="RTL">التهاب القولون الغشائي الكاذب (التهاب الأمعاء)</li><li dir="RTL">متلازمة كثرة الوحيدات (كثرة الوحيدات الزائفة)</li><li dir="RTL">تغيرات في تعداد الدم، بما في ذلك نقص شديد في خلايا الدم البيضاء (ندرة المحببات) وفقر الدم الشديد.</li><li dir="RTL">تفاعلات فرط الحساسية، التورم الوعائي (تورم الشفتين، والأجفان، والوجه، واللسان، والحلق)، داء المصل (تفاعل حساسية متأخر)</li><li dir="RTL">نقص حمض الفوليك</li><li dir="RTL">اضطراب الجهاز العصبي، التهاب الدماغ، الاعتلال الدماغي (مرض الدماغ)، تغير حاسة الشم، التهاب عضلة القلب</li><li dir="RTL">التهاب التأمور، أكسجة الدم التي تؤدي إلى تغير لون الجلد، والشفتين، والأغشية المخاطية إلى لون مائل للزرقة (الازرقاق) والشحوب</li><li dir="RTL">أمراض رئوية مختلفة (مثل التهاب الأسناخ الرئوية المليف)، ألم في الفم والحلق</li><li dir="RTL">التهاب البنكرياس، تفاقم حالة التهاب القولون التقرحي</li><li dir="RTL">خلل وظيفي بالكبد، يحدث أحيانًا بشكل مفاجئ، وفشل الكبد، وضيق القنوات الصفراوية في الكبد، وبطء تدفق الصفراء في المرارة</li><li dir="RTL">الطفح الجلدي الناتج عن الدواء (التفاعل الدوائي المصحوب بكثرة اليوزينيات وأعراض جهازية - انظر أيضًا الاحتياطات عند استعمال سالازوبيرين إي إن)، الطفح الجلدي، احمرار الجلد، التهاب الجلد الشديد المصحوب بتقشر (التهاب الجلد التقشري)، الإصابة بتفاعلات جلدية عند التعرض للشمس</li><li dir="RTL">متلازمة سيستمك لوباس ايريثماتوزيس (SLE) (مرض مناعة ذاتية)</li><li dir="RTL">خلل وظيفي بالكلى، وجود دم في البول، وجود بلورات في البول، حصوات الكلى</li><li dir="RTL">تغير لون الجلد وسوائل الجسم إلى اللون الأصفر (مثل العرق، واللعاب، والبول، وسائل الدموع) وبالتالي اصفرار العدسات اللاصقة اللينة</li><li dir="RTL">تكوُّن أجسام مضادة تهاجم أنسجة الجسم (تُسمى الأجسام المضادة الذاتية)</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بعدوى مصحوبة بأعراض مثل الحمى والتدهور الخطير في حالتك العامة أو الحمى المصحوبة بأعراض عدوى موضعية مثل التهاب الحلق/البلعوم/الفم أو مشكلات بالتبول، ينبغي لك زيارة طبيبك فورًا. سيتم إجراء اختبار دم للتحقق من احتمالية نقص خلايا الدم البيضاء (ندرة المحببات). من المهم إبلاغ طبيبك بشأن الدواء الذي تتناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي التوقف عن تناول سالازوبيرين إي إن وزيارة طبيبك على الفور إذا أصبت بأعراض التورم الوعائي، مثل</p><p dir="RTL">&bull; تورم الوجه، أو اللسان، أو البلعوم</p><p dir="RTL">&bull; صعوبة البلع</p><p dir="RTL">&bull; الشرى وصعوبات في التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن حدوث تفاعلات جلدية قد تكون مهددة للحياة (متلازمة ستيفنز جونسون وتقشر الأنسجة المتموتة البشروية التسممي) (انظر الاحتياطات عند استعمال سالازوبيرين إي إن).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المملكة العربية السعودية:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em>مركز اتصال الهيئة العامة للغذاء والدواء: ١٩٩٩٩</p><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em>البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp; الموقع الإلكتروني: <strong>&nbsp;https://ade.sfda.gov.sa/</strong><strong>&nbsp;&nbsp;</strong></p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى:</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تستخدم هذا الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور. صلاحية المستحضر ٤٨ شهر.</strong><br /><br /><strong>يحفظ عند درجة حرارة اقل من ٢٥ درجة مئوية.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي سلفاسالازين. يحتوي القرص الواحد على ٥٠٠ ملجم سلفاسالازين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: نشا الذرة، وستيارات المغنيسيوم، وبوفيدون، السيليكا اللامائي الغروي (ثاني أكسيد السيليكون)، وفثالات أسيتات السليولوز، وبروبيلين جليكول (انظر القسم <strong>٢</strong> &quot; يحتوي سالازوبيرين إي إن على بروبيلين جليكول&quot;)، وشمع العسل الأبيض، وشمع الكرنوبا، وأحادي ستيارات الجليسيرول، وماكروجول <strong>٢</strong>٠٠٠٠، وتلك.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">حاوية (من البولي إيثيلين عالي الكثافة) مزودة بغطاء لولبي (من البولي بروبيلين)، تحتوي على ١٠٠ وحدة. الغطاء به شق لتسهيل الفتح باستخدام أداة مثل القلم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القرص ذو شكل دائري أصفر اللون، ومحفور عليه رمز.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق:</strong></p><p dir="RTL"><strong>Pfizer AB, Sweden</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجهة المصنعة:</strong></p><p dir="RTL"><strong>&nbsp;</strong>&nbsp;<strong>Recipharm Uppsala AB, Sweden</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو/حزيران ٢٠٢٣
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Salazopyrin EN 500 mg gastro-resistant tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One gastro-resistant tablet contains 500 mg sulfasalazine

Excipient with known effect
One gastro-resistant tablet Salazopyrin EN 500 mg contains 5 mg propylene glycol.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro-resistant tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Active rheumatoid arthritis that cannot be controlled with anti-inflammatory drugs. Ulcerative Colitis. Crohn&rsquo;s disease. Pyoderma gangrenosum.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Inflammatory bowel disease</em></p><p>The dose should be adjusted to the severity of the disease and the tolerance.</p><p>It is recommended that patients who have not previously been treated with Salazopyrin EN gradually increase their dose over a period of a few weeks. The tablets should preferably be taken with meals and distributed evenly throughout the day. Salazopyrin EN is a gastro-resistant tablet specially developed for patients with active rheumatoid arthritis and for patients who suffer from gastrointestinal adverse effects from Salazopyrin tablets. The gastro-resistant tablets must be swallowed whole.</p><p>&nbsp;</p><p><em>Acute attacks</em></p><p><em>Adults:</em> Severe attacks: 2-4 tablets 3-4 times daily.<br />Moderate and mild attacks: 2 tablets 3-4 times daily.<br /><em>Children:</em> 40-60 mg/kg of body weight per day, divided into 3-6 doses.</p><p>&nbsp;</p><p><em>Prophylactic treatment</em></p><p><em>Adults:</em> When the disease is in remission, a maintenance dose is prescribed to keep the patient asymptomatic, normally 2 tablets 2 (-3) times daily. Treatment with this dose should be administered continually, as lifelong treatment, unless undesirable effects occur. If the disease worsens, the dose should be increased to 2 (-4) tablets 3-4 times daily.</p><p><em>Children:</em> 20-30 mg/kg of body weight per day, divided into 3-6 doses.</p><p>&nbsp;</p><p><em>Active rheumatoid arthritis</em><br />When treating rheumatoid arthritis, only Salazopyrin EN must be used. The tablets should preferably be taken with meals.</p><p><em>Adults:</em> The dose should be adapted individually. The effective dose varies between 1 and 3 grammes per day. The most common dose is 2 gastro-resistant tablets twice daily. When initiating treatment, the dose should be increased as shown in the following table:<br />&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 1-4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 5-8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Day 9 and later<br />Morning&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 gastro-resistant tablet 1 gastro-resistant tablet 2 gastro-resistant tablets</p><p>&nbsp;</p><p>Evening&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 gastro-resistant tablet 2 gastro-resistant tablets 2 gastro-resistant tablets</p><p>&nbsp;</p><p>If the patient has not responded to treatment within 2-3 months, the dose may be increased to 3 g per day. Patients who suffer adverse effects from the gastrointestinal tract may temporarily reduce their dose.<br /><em>Children: </em>No recommendation may currently be given for the treatment of juvenile chronic arthritis.</p><p>&nbsp;</p><p><em>Treatment monitoring:</em></p><p>It is recommended that blood picture and liver function tests are performed initially and every two weeks during the first three months of treatment. Tests are then carried out every four weeks in the following three-month period. Blood picture and liver function tests are then performed every three months. Renal function tests are recommended initially and at regular intervals during treatment.</p><p>Blood picture changes that may be related to folic acid deficiency may be normalised through the administration of folinic acid (leucovorin).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any other excipient listed in section 6.1. Acute intermittent porphyria.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Serious infections associated with myelosuppression, including sepsis and pneumonia, have been reported. Patients who develop a new infection while undergoing treatment with sulfasalazine should be monitored closely. Administration of sulfasalazine should be discontinued if a patient develops a serious infection. Caution should be exercised when considering the use of sulfasalazine in patients with a history of recurring or chronic infections or with underlying conditions which may predispose patients to infections.</p><p>It is recommended that complete blood counts (including differential white cell counts) and liver function tests are performed initially and every two weeks during the first three months of treatment. Tests are then carried out every four weeks in the following three-month period. Blood counts and liver function tests are then performed every three months or when it is clinically indicated. It is recommended that the renal function (including urine analyses) is tested initially and every four weeks during the first three months of treatment. The renal function is then tested when it is clinically indicated. If clinical symptoms such as sore throat, fever, pallor, purpura or jaundice occur during sulfasalazine treatment, this may indicate bone marrow suppression, haemolysis or hepatotoxicity. Treatment with sulfasalazine should be discontinued while awaiting the results of blood tests, see also section 4.4 &ldquo;Interference with laboratory testing&rdquo;. Blood picture changes that may be related to folic acid deficiency may be normalised through the administration of folinic acid (leucovorin).</p><p>&nbsp;</p><p>Sulfasalazine should be administered with caution to patients with impaired renal or hepatic function and to patients with a severe allergy or asthma. As sulfasalazine may cause haemolytic anaemia, it should be administered with caution in the treatment of patients with G-6-PD deficiency.</p><p>&nbsp;</p><p>Desensitisation may be considered in individual patients who report milder hypersensitivity reactions. The drug must be discontinued in patients who report more severe reactions.</p><p>&nbsp;</p><p>Severe hypersensitivity reactions may include internal organ involvement, such as hepatitis, nephritis, myocarditis, mononucleosis-like syndrome, hematological abnormalities (including hematophagic histiocytosis), and/or pneumonitis including eosinophilic infiltration.</p><p>&nbsp;</p><p>Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with the use of sulfasalazine. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment. If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, Salazopyrin EN treatment should be discontinued. The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. If the patient has developed SJS or TEN with the use of Salazopyrin EN, Salazopyrin EN must not be re-started in this patient at any time.</p><p>&nbsp;</p><p>&nbsp;</p><p>Severe, life-threatening systemic hypersensitivity reactions such as drug rash with eosinophilia and systemic symptoms (DRESS) have been reported in patients taking sulfasalazine. It is important to note that early signs of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not visible. The patient should be examined immediately if these symptoms occur. Sulfasalazine treatment should be discontinued if another cause for the symptoms cannot be identified.</p><p>&nbsp;</p><p><em>Interference with laboratory testing</em></p><p>Several reports of possible interference with measurements, by liquid chromatography, of urinary normetanephrine causing a false-positive test result have been observed in patients exposed to sulfasalazine or its metabolite, mesalamine/ mesalazine.</p><p>&nbsp;</p><p>Sulfasalazine or its metabolites may interfere with ultraviolet absorbance, particularly at 340 nm, and may cause interference with some laboratory assays that use NAD(H) or NADP(H) to measure ultraviolet absorbance around that wavelength. Examples of such assays may include urea, ammonia, LDH, &alpha;-HBDH and glucose. It is possible that alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase-muscle/brain (CK-MB), glutamate dehydrogenase (GLDH), or thyroxine may also show interference when sulfasalazine treatment is given at high doses. Consult with the testing laboratory regarding the methodology used. Caution should be exercised in the interpretation of these laboratory results in patients who are receiving sulfasalazine. Results should be interpreted in conjunction with clinical findings.</p><p>&nbsp;</p><p>Because sulfasalazine causes crystalluria and kidney stone formation, adequate fluid intake must be maintained.</p><p>&nbsp;</p><p><u>Excipient information</u></p><p>Salazopyrin EN 500 mg tablets contain propylene glycol (see section 2).</p><p>&nbsp;</p><p>Examples of propylene glycol exposure based on daily dose (see section 4.2) are as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16 Salazopyrin EN 500 mg tablets administered to an adult weighing 70 kg would result in a propylene glycol exposure of 1.14 mg/kg/day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 Salazopyrin EN 500 mg tablets administered to a 6 year-old child weighing 20 kg would result in a propylene glycol exposure of 0.50 mg/kg/day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reduced absorption of digoxin has been reported during concomitant treatment with sulfasalazine. Folic acid deficiency may occur as sulfasalazine inhibits the absorption of folic acid.</p><p>Rifampicin reduces the concentration of sulfapyridine in plasma during sulfasalazine treatment, probably due to an enzyme-inducing effect. The clinical significance is unclear.</p><p>&nbsp;Bone marrow suppression and leukopenia have been reported when mercaptopurine or azathioprine and oral sulfasalazine have been administered concomitantly. <em>In vitro</em> studies show that sulfasalazine inhibits thiopurine methyltransferase (TPMT), which is involved in the metabolism of mercaptopurine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Fertility</em></p><p>There is no available data on fertility.</p><p><em>&nbsp;</em></p><p><em>Pregnancy </em></p><p>Reproduction studies on rats and rabbits indicate no risk of harm to the foetus.</p><p>Sulfasalazine passes via the placenta in such quantities that the foetus may be expected to have the same plasma concentrations as the mother, which may also put the foetus at risk of undesirable effects.</p><p>&nbsp;</p><p>As oral sulfasalazine inhibits the absorption and metabolism of folic acid, this may cause folic acid deficiency (see section 4.4). There have been reports of children with neural tube defects whose mothers were exposed to sulfasalazine during pregnancy, although the importance of sulfasalazine for these defects has not been proven.</p><p>&nbsp;</p><p>As risks associated with use during pregnancy cannot be completely ruled out, treatment should only be given after careful consideration.</p><p>&nbsp;</p><p><em>Lactation </em></p><p>Low levels of sulfasalazine and sulfapyridine pass into breast milk. Caution should be used particularly when breast-feeding premature infants with G-6-PD deficiency. Bloody stools and diarrhoea have been reported in infants being breast-fed by women who had been treated with sulfasalazine. In cases where this was reported, the bloody stools or diarrhoea in the infant ceased when the nursing woman discontinued treatment with sulfasalazine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No effects have been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects, normally from the gastrointestinal tract or in the form of headaches, are seen in approximately one third of the patients being treated with sulfasalazine. Some undesirable effects are dose-dependent. Approximately 75% of the undesirable effects occur within the first three months of starting therapy.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Organ system class</strong></p></td><td style="vertical-align:top"><p><strong><em>Common</em></strong></p><p><em>(</em>&sup3;<em>1/100, &lt;1/10)</em></p></td><td style="vertical-align:top"><p><strong><em>Uncommon </em></strong><em>(</em>&sup3;<em>1/1,000, &lt;1/100)</em></p></td><td style="vertical-align:top"><p><strong><em>Rare </em></strong></p><p><em>(</em>&sup3;<em>1/10,000, &lt;1/1,000)</em></p></td><td style="vertical-align:top"><p><strong><em>Unknown frequency</em></strong></p><p><em>(Cannot be estimated from the available data)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pseudomembranous colitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>leukopenia</p></td><td style="vertical-align:top"><p>thrombocytopenia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;megaloblastic anaemia, aplastic anaemia.</p></td><td style="vertical-align:top"><p>pancytopenia, haemolytic anaemia, macrocytosis, agranulocytosis, mononucleosis-like syndrome*<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>facial oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anaphylactic reactions, including isolated cases of anaphylactic shock*.</p><p>angioedema, including oedema of the larynx/pharynx. serum sickness</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>loss of appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>folate deficiency*<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>depression</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Central and peripheral nervous system disorders</strong></p></td><td style="vertical-align:top"><p>headache, dizziness, taste alterations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>peripheral neuropathy, aseptic meningitis, encephalopathy, smell alterations</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pericarditis, cyanosis, myocarditis *<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>cough</p></td><td style="vertical-align:top"><p>dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>interstitial lung disease*, fibrosing alveolitis, eosinophilic infiltration of the lungs, oropharyngeal pain*<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pallor*<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain, nausea, bloatedness, diarrhoea, vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pancreatitis, worsening of ulcerous colitis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>jaundice<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>hepatitis<sup>&dagger;</sup>, hepatic failure*, fulminant hepatitis*, cholestasis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>urticaria, itching, purpura<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>alopecia</p></td><td style="vertical-align:top"><p>epidermal necrolysis (Lyell&rsquo;s syndrome)<sup> &dagger;</sup>, Stevens-Johnson syndrome (SJS)<sup>&dagger;</sup>, nail alterations</p></td><td style="vertical-align:top"><p>drug rash with eosinophilia and systemic symptoms (DRESS)*<sup>&dagger;</sup>, exanthema, erythema, exfoliative dermatitis, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculo-skeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>arthralgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>SLE syndrome</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>proteinuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nephritis.</p></td><td style="vertical-align:top"><p>nephrotic syndrome, haematuria, crystalluria<sup>&dagger;</sup>, interstitial nephritis, nephrolithiasis*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>reversible oligospermia<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General symptoms and/or administration site symptoms</strong></p></td><td style="vertical-align:top"><p>fever<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>yellow discolouration of skin and bodily fluids have been reported and also yellow discolouration of soft contact lenses</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>transient elevation of liver enzymes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>induction of autoantibodies</p></td></tr></tbody></table><p>* undesirable effects identified after introduction into the market</p><p><sup>&dagger; </sup>see section 4.4 Special warnings and precautions for use</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (SCARS); Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported (see section 4.4).</p><p>&nbsp;</p><p>It may sometimes be difficult to distinguish between an undesirable effect of the drug and complications from the underlying diseases, particularly if they manifest in other organ systems. Cases of aseptic meningitis have only been reported in patients with a rheumatic disease.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local country requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDACall center : 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>25 g sulfasalazine in an adult resulted in mild intoxication following early gastric lavage.</p><p>&nbsp;</p><p>The following applies to sulfonamides in general:</p><p>&nbsp;</p><p><em>Toxicity: </em>Individual instances of patients ingesting high amounts have resulted in severe poisoning in rare cases.</p><p>43 g in a 24-hour period in an adult resulted in lethal intoxication (sulfhaemoglobinaemia and methaemoglobinaemia). Note: allergic symptoms may occur. Risk of kernicterus in newborns.</p><p>&nbsp;</p><p><em>Symptoms:</em> Nausea, vomiting. Crystalluria, haematuria, oliguria and anuria. Hypoglycaemia, in individual cases methaemoglobinaemia, cyanosis, liver damage, sulfhaemoglobinaemia. CNS damage. Hypersensitivity reactions, such as blood picture changes (lethal agranulocytosis), urticaria, polyneuritis, cerebral symptoms.</p><p>&nbsp;</p><p><em>Treatment:</em> If required, gastric lavage at an early stage, charcoal. Substantial intravenous fluid administration to keep diuresis at a high level, alkalinisation with sodium bicarbonate intravenously. The risk of oliguria and anuria must be monitored. Dialysis in the event of anuria. In the event of marked methaemoglobinaemia (cyanosis), methylthionine 1-2 mg/kg slowly intravenously. Symptomatic treatment otherwise. In severe cases of sulfhaemoglobinaemia, an exchange transfusion may be performed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacotherapeutic group:</em> Intestinal antiinflammatory agents, <em>ATC code: </em>A07E C01</p><p>&nbsp;</p><p>Sulfasalazine has an anti-inflammatory, immunosuppressive and antibacterial effect and is used to inhibit inflammatory conditions, particularly those localised in the intestinal mucosa. The primary effect of sulfasalazine administration is considered to be the anti-inflammatory effect of locally formed mesalazine. An immunosuppressive effect has also been shown by inhibiting lymphocyte and granulocyte metabolism and by inhibiting different enzyme systems through all three of the components (sulfasalazine, sulfapyridine, mesalazine). The bacteriostatic activity of sulfapyridine formed locally in the colon may have a clinical effect. Both the aerobic and the anaerobic bacterial flora are affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following oral administration, part of the dose (approximately 20% of an administered dose) is absorbed in the small intestine that is subsequently excreted through enterohepatic circulation. Maximum serum concentration is reached after 3-6 hours, with protein binding at approximately 99%. There are significant individual differences in serum concentration. There is a moderate tendency to accumulation; the serum concentration is insignificant 24 hours after a single dose of sulfasalazine. A few percent of the dose is excreted in the urine.</p><p>&nbsp;</p><p>Sulfasalazine is split by intestinal bacteria in the colonic lumen into two main metabolites, sulfapyridine and mesalazine (5-aminosalicylic acid). Sulfapyridine is absorbed rapidly; it is partly metabolised in the liver into inactive acetyl sulfapyridine and is primarily excreted as this in the urine. Non-acetylated sulfapyridine is partly bound to serum proteins and the maximum serum concentration is reached after 12 hours. Sulfapyridine shows a certain tendency for accumulation; the serum concentration only disappears completely 3 days after discontinuation.</p><p>The degree of acetylation of sulfapyridine is genetically determined. Patients with slow acetylation have higher serum concentrations of free sulfapyridine and they are therefore more likely to develop adverse effects. Mesalazine (5-aminosalicylic acid) is absorbed to a lesser extent; the serum concentration is approximately 1 &micro;g/ml. 15% of the dose is excreted in the urine. The majority, 75%, remains in the colonic lumen and is excreted as 5-aminosalicylic acid in the faeces.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Povidone 16 mg</p><p>Maize starch, pregelatinized 90.80 mg</p><p>Magnesium stearate 10.90 mg</p><p>Colloidal anhydrous Silica 3.27 mg</p><p>Cellulose acetate phthalate 20 mg</p><p>Propylene glycol 5 mg</p><p>White beeswax 3 mcg<br />Carnauba wax 6 mcg</p><p>Glyceryl monostearate 5 mcg<br />Macrogol 8 mcg</p><p>Talc 13 mcg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Salazopyrin EN after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.

Shelf life: 48 Months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25℃.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Yellow, orange, elliptical, convex, enteric-coated tablets, with the letters &ldquo;KPh&rdquo; on one face, and the product code &ldquo;102&rdquo; on the other.</p><p>&nbsp;</p><p>Container with a screw top lid made of HD polyethylene and/or polypropylene.</p><p>&nbsp;</p><p>The lid has a notch so that it can be opened easily with a pen, for example.</p><p>&nbsp;</p><p>Pack size: 100 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>No special precautions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pfizer AB, Sweden

MANUFACTURER 
 Recipharm Uppsala AB, Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>